2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow IMA950: new trials by email Literature Review of IMA950 trials Research Report on IMA950
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma | Phase 1 | Terminated | Nicholas Butowski | 14 | 2017-04-03 | 2024-06-14 |
| Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma Cyclophosphamide, IMA950 plus GM-CSF, IMA950 - Glioblastoma | Phase 1 | Terminated | Immatics Biotechnologies GmbH | 6 | 2011-08-01 | 2014-05-19 |
| Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide - Brain and Central Nervous System Tumors | Phase 1 | Completed | Cancer Research UK | 45 | 2010-07-01 | 2015-10-14 |
Glioblastoma (2) · Astrocytoma (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Gliosarcoma (1) · Lymphoma, Follicular (1) · Oligodendroglioma (1)
Cancer Research UK (1) · Immatics Biotechnologies GmbH (1) · Nicholas Butowski (1)
United States (2) · United Kingdom (1)
Hideho Okada, MD, PhD (1) · Nicholas Butowski, MD (1) · Roy Rampling, MD, PhD (1) · Teri Kreisl, MD (1)
R21CA233856 (1)